Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production

Ítems similars

• Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
  per: Pico de Coaña, Yago, et al.
  Publicat: (2015)
• Ipilimumab treatment enhances CD4+ T cell activation while decreasing Treg and MDSC frequency in advanced melanoma patients
  per: Pico de Coaña, Yago, et al.
  Publicat: (2014)
• Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
  per: de Coaña, Yago Pico, et al.
  Publicat: (2017)
• Inhibiton of tumor-derived prostaglandin-e2 prevents the induction of human myeloid-derived suppressor cells (MDSCs) and rescues anti-tumor immunity
  per: Mao, Yumeng, et al.
  Publicat: (2014)
• High expression of ID1 in monocytes is strongly associated with phenotypic and functional MDSC markers in advanced melanoma
  per: Melief, Jeroen, et al.
  Publicat: (2020)